Purpose: Lafora disease (LD) is an autosomal recessive form of progressive myoclonus epilepsy with onset in childhood or adolescence and with fatal outcome caused by mutations in two genes: EPM2A and NHLRC1. The aim of this study was to characterize the mutation spectrum in a cohort of unrelated patients with presumed LD.

Methods: Sequencing of the two genes and search for large rearrangements was performed in 46 unrelated patients with suspected LD, 33 originating from France and the others from different countries. Patients were classified into two groups according to the clinical presentation.

Results: Mutations of various types were found in EPM2A in 10 patients and in NHLRC1 in 4 patients. Mutations were found in 14 (93%) of 15 patients with classical clinical and electroencephalography (EEG) presentation of LD and in no patients with an atypical presentation. Ten mutations were novel, including the first substitution reported in a donor splice site of EPM2A, leading to the deletion of exon 2 at the RNA level. Four large deletions, including two deletions of exon 2 with different sizes and breakpoints, were found in EPM2A, corresponding to 20% of the alleles of this gene.

Discussion: We described several novel mutations of EPM2A and NHLRC1 and brought additional data to the genetic epidemiology of LD. This study emphasized the high mutation rate in patients with classical LD as well as the high negativity rate of skin biopsy.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1528-1167.2010.02692.xDOI Listing

Publication Analysis

Top Keywords

epm2a nhlrc1
12
novel mutations
8
mutations epm2a
8
lafora disease
8
patients
8
unrelated patients
8
patients classical
8
epm2a
6
mutations
5
nhlrc1
4

Similar Publications

Identification of biallelic intronic EPM2A mutations in a Lafora disease kindred.

J Hum Genet

November 2024

Department of Neurology, Qilu Hospital of Shandong University, 250012, Jinan, China.

Article Synopsis
  • Lafora disease (LD) is a serious genetic disorder leading to seizures, myoclonus, behavioral changes, and eventual dementia, caused primarily by mutations in the EPM2A and NHLRC1 genes.
  • This study focuses on a patient with LD and identifies specific intronic mutations in EPM2A that impact mRNA splicing, leading to the disease's symptoms.
  • The research highlights the importance of genetic testing in diagnosing LD and expands the understanding of how certain mutations in non-coding regions can contribute to the condition.
View Article and Find Full Text PDF

VAL-1221 for the treatment of patients with Lafora disease: study protocol for a single-arm, open-label clinical trial.

BMJ Open

October 2024

IRCCS Istituto Delle Scienze Neurologiche di Bologna - Full member of the ERN EpiCARE, Bologna, Italy

Introduction: Lafora disease (LD) is an ultrarare fatal progressive myoclonic epilepsy, causing drug-resistant epilepsy, myoclonus and psychomotor deterioration. LD is caused by mutations in EPM2A or NHLRC1, which lead to the accumulation of polyglucosans in the brain and neurodegeneration. There are no approved treatments for LD.

View Article and Find Full Text PDF

Genetic profile of progressive myoclonic epilepsy in Mali reveals novel findings.

Front Neurol

September 2024

Faculté de Médecine et d'Odontostomatologie, Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), Bamako, Mali.

Background And Objectives: Progressive myoclonic epilepsy (PME) is a group of neurological disorders characterized by recurrent myoclonic seizures with progressive neurological deterioration. We investigated the genetics of three unrelated patients with PME from Mali, a country in sub-Saharan Africa highly underrepresented in genetic and genomic research.

Methods: Participants were carefully examined and phenotyped.

View Article and Find Full Text PDF

Neuromuscular junction dysfunction in Lafora disease.

Dis Model Mech

October 2024

Department of Biological Sciences and Bioengineering, Indian Institute of Technology, Kanpur 208016, India.

Lafora disease (LD), a fatal neurodegenerative disorder, is caused by mutations in the EPM2A gene encoding laforin phosphatase or NHLRC1 gene encoding malin ubiquitin ligase. LD symptoms include epileptic seizures, ataxia, dementia and cognitive decline. Studies on LD have primarily concentrated on the pathophysiology in the brain.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!